Inhibrx Biosciences, Inc. (INBX)

INBX gained 8.56% while closely rated peers mostly saw modest single-digit moves (e.g., PRTA +2.89%, SLDB -1.6%). Momentum scans show one peer up and one down, pointing to a stock‑specific reaction rather than a broad biotech move. ... Earnings releases have usually triggered moderate ...

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($2.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.47). Equities research analysts anticipate that Inhibrx ...

Inhibrx Biosciences cut its Q1 2026 net loss to $33.4M, ended with $161.7M cash, added $75M in term debt, filed an ozekibart BLA, and reported strong INBRX-106 head and neck cancer data.

Why is International Business Machines stock surging today?

FORECAST CHANGESRECOMMENDATIONSThis summary was machine generated from LSEG data May 14 at 08:58 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact ...